[ad_1]
NORWALK, CT., February 19, 2026 /PRNewswire/ — Lifespan Vision Ventures, an investment firm focused on therapies that improve human health, today announced that it co-led the oversubscribed $3.7 million pre-seed financing of Sift Biosciences alongside Freeflow Ventures, with participation from Valuence Ventures, Eisai Innovation, SBI US Gateway Fund and other early investors.
Sift Biosciences is developing a peptide-based immunotherapy platform designed to exploit pre-existing immune memory. The company’s approach aims to generate more consistent immune engagement by activating memory T cells that already exist in patients, with potential applications in oncology and autoimmune diseases. Sift is initially advancing programs in immunologically “cold” solid tumors, including microsatellite-stable colorectal and ovarian cancers, while also exploring immune disease programs in which more selective control of immune responses may be therapeutic.
“This funding will support in vivo efficacy studies, the expansion of our AI-powered peptide discovery engine, and the selection of lead candidates,” said Clare Lou, Ph.D., CEO and co-founder of Sift Biosciences. “We are excited to partner with Lifespan Vision Ventures and this strong syndicate of investors as we advance our initial pipeline to the clinic.”
“We are pleased to support Sift as they bring a clear vision to immunology with a platform built at scale,” said Altar Munis, Ph.D., Partner at Lifespan Vision Ventures. “The platform is designed to engage antigen-experienced memory T cells and tune the magnitude and phenotype of the response, with potential applications beyond oncology in autoimmunity and broader immune dysfunction that increases with age.”
As part of the financing, Altar Munis, Ph.D., partner at Lifespan Vision Ventures, and Kevin Barrett, managing partner at Freeflow Ventures will join the Sift Biosciences board of directors.
About Lifespan Vision Ventures
Lifespan Vision Ventures is a global venture capital firm that invests in early-stage biotechnology companies developing breakthrough technologies to prevent and treat age-related diseases. The company partners with visionary founders to deliver science-based solutions that promote healthy aging and prolong human health.
Contact: info@lifespanvision.com
SOURCE LifeSpan Vision Ventures
[ad_2]
Source: PR Newswire
